Home » Stocks » DYN

Dyne Therapeutics, Inc. (DYN)

Stock Price: $19.61 USD 0.05 (0.26%)
Updated November 25, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 891.18M
Revenue (ttm) n/a
Net Income (ttm) -54.08M
Shares Out 45.45M
EPS (ttm) -1.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 25
Last Price $19.61
Previous Close $19.56
Change ($) 0.05
Change (%) 0.26%
Day's Open 19.55
Day's Range 19.19 - 20.12
Day's Volume 106,045
52-Week Range 15.60 - 27.11

More Stats

Market Cap 891.18M
Enterprise Value 521.51M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 45.45M
Float 16.96M
EPS (basic) n/a
EPS (diluted) -1.19
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.39
Revenue n/a
Operating Income n/a
Net Income -54.08M
Free Cash Flow n/a
Net Cash 369.67M
Net Cash / Share 8.13
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(74.66% upside)
Current: $19.61
Target: 34.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-13.83-4.80
Net Income-14.86-4.81
Shares Outstanding2.440.47
Earnings Per Share-6.08-10.15
Operating Cash Flow-11.83-4.16
Capital Expenditures-1.65-0.13
Free Cash Flow-13.48-4.30
Cash & Equivalents14.638.12
Net Cash / Debt14.638.12
Book Value14.04-4.88
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Dyne Therapeutics, Inc.
Country United States
Employees 36
CEO Joshua T. Brumm

Stock Information

Ticker Symbol DYN
Stock Exchange NASDAQ
Sector Health Technology
Industry Biotechnology
Unique Identifier NASDAQ: DYN
IPO Date September 17, 2020


Dyne Therapeutics, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.